Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRY-614 plus Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors
NCT04074967Phase 2Active, not recruiting
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pexmetinib in solid tumor, renal cell carcinoma (RCC), melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC). Started Jun 2020; status: active, not recruiting.
02
Drugs
pexmetinib
03
Conditions
solid tumorrenal cell carcinoma (RCC)melanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04074967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074967.